Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma

H. Asaoku, M. Kawano, K. Iwato, O. Tanabe, H. Tanaka, T. Hirano, T. Kishimoto, A. Kuramoto

研究成果: Article査読

38 被引用数 (Scopus)

抄録

Human myeloma cells freshly isolated from 40 patients with IgG multiple myeloma (MM, 10 in stage I and 30 in stage III), were cultured for 48 hours with recombinant B cell stimulatory factor 2 (rBSF-2)/interleukin-6 (IL-6), which is considered a major growth factor for myeloma cells. Uptake of 3H-thymidine by these purified myeloma cells was measured, and BSF-2 response was evaluated by stimulation index and Δcpm induced by rBSF-2. Myeloma cells from cases in stage I responded to rBSF-2 better than those in stage III. Moreover rBSF-2 responders also showed better response to chemotherapy. Therefore, these results suggest that in vitro response of myeloma cells to BSF-2 correlates with disease progression and clinical response in patients of MM.

本文言語English
ページ(範囲)429-432
ページ数4
ジャーナルBlood
72
2
DOI
出版ステータスPublished - 1988

ASJC Scopus subject areas

  • 生化学
  • 免疫学
  • 血液学
  • 細胞生物学

フィンガープリント

「Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル